Eli Lilly Alzheimer's Drug Delayed as FDA Plans Advisory Panel Meeting

Eli Lilly Alzheimer's Drug Delayed as FDA Plans Advisory Panel Meeting

[ad_1]

The timing of the agency’s expected action on the donanemab drug would be postponed beyond the first quarter, the company said.

[ad_2]

Leave a Reply

Your email address will not be published. Required fields are marked *